Diffuse Large B Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma and is highly aggressive if untreated. Traditional diagnostics rely heavily on histopathology and imaging, which often detect disease at later stages.

The DLBCL Assay focuses on immune and molecular biomarkers that signal lymphoma development and progression. By identifying these patterns, the assay provides early diagnostic support, treatment guidance, and recurrence monitoring, improving the outlook for patients with or at risk for DLBCL.

Why This Test Matters

Key Benefits

Standard scans can miss early immune and molecular changes. The Diffuse Large B Cell Lymphoma Assay detects these disruptions at the molecular level so patients and clinicians can act early.

Early Immune Profiling

Detects molecular immune signals associated with lymphoma progression.

Precision Therapy Guidance

Provides evidence to support immunotherapy, targeted therapy, and chemoimmunotherapy strategies.

Monitoring Capability

Tracks immune and tumor microenvironment activity during treatment and remission.

Complementary Evidence

Enhances biopsy and imaging findings with immune-molecular analysis.

Physician-Ready Report Included

Results in
10-14 days

Reliable Results You Can Trust

Biomarkers Assessed

The Diffuse Large B Cell Lymphoma Assay panel measures a targeted range of biomarkers to detect immune activity, tumor-promoting inflammation, and lymphoma progression:

  • Immune checkpoint activity (PD-L1, CTLA-4 pathways)

  • B-cell proliferation and survival proteins

  • Tumor-promoting cytokines and inflammatory markers (IL-6, TNF-α, CRP)

  • Angiogenesis and prometastatic signaling proteins (VEGF, MMPs)

  • Tumor microenvironment immune dysregulation markers

Download a Sample Report

How It Works

Process

From registration to results, the process is simple, secure, and stress-free. One blood draw gives you answers that imaging can’t.

01

Order & Registration

Secure registration through Persona Biomed’s patient portal.

02

Sample Collection

Blood draw at an approved lab or via mobile phlebotomy.

03

Laboratory Analysis

High-sensitivity assays evaluate immune-molecular patterns linked to lymphoma.

04

Results Delivery

Comprehensive clinical report provided in the portal, with physician-ready data and AI-friendly patient summaries.

Who Should Consider This Test

who is this for

This test is intended for individuals who may be at risk, are experiencing related symptoms, or wish to take a proactive approach to their health, such as:

  • Patients with suspected or diagnosed non-Hodgkin lymphoma.

  • Individuals with abnormal lymph node findings or unexplained systemic symptoms (fever, weight loss, night sweats).

  • Patients undergoing treatment for DLBCL requiring biomarker monitoring.

  • Survivors in remission who need long-term recurrence tracking.

Register Now for Diffuse Large B Cell Lymphoma Assay

Register now for the Diffuse Large B Cell Lymphoma Assay to detect immune-molecular signals of lymphoma and guide precision oncology care.

Register now